Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries

Pulmonary Therapy

Volumn 2, Issue 1, 2016, Pages 59-72

  Punekar, Yogesh Suresh ^a   Mullerova, Hana ^a   Small, Mark ^b   Holbrook, Tim ^b   Wood, Robert ^b   Naya, Ian ^a   Valle, Manuel ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ADELPHI REAL WORLD   (United Kingdom)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Chronic obstructive pulmonary disease (COPD); Costs; Dyspnoea; Prevalence; Resource use

Indexed keywords

EID: 84995677174     PISSN: 23641754     EISSN: 23641746     Source Type: Journal    
DOI: 10.1007/s41030-016-0011-5     Document Type: Article

References (50)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. Available at http://goldcopd.org/guidelines/guidelines-resources.html. Accessed Jan 13, 2016.
2. NCD mortality and morbidity. Geneva: World Health Organization. Available from: http://www.who.int/gho/ncd/mortality_morbidity/en/. Accessed on Jan 13, 2016.
3. The top 10 causes of death. Geneva: World Health Organization. Available from URL: http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed Jan 13, 2016.
4. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–72. DOI: 10.1183/09031936.00051110
5. Mollaoglu M, Fertelli TK, Tuncay FO. Fatigue and disability in elderly patients with chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr. 2011;53:e93–8. DOI: 10.1016/j.archger.2010.07.001
6. Punekar YS, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M. Implications of chronic obstructive pulmonary disease (COPD) on patients’ health status: a western view. Respir Med. 2007;101:661–9. DOI: 10.1016/j.rmed.2006.06.001
7. Hardie GE, Jonson S, Gold WM, Carrieri-Kolhman V, Boushey H. Ethnic differences: word descriptors used by African American and white asthma patients during induced bronchoconstriction. Chest. 2000;117:928–9. DOI: 10.1378/chest.117.4.935
8. Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS ONE. 2014;9(1):e85540. doi:10.1371/journal.pone.0085540. DOI: 10.1371/journal.pone.0085540
9. Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and economic burden of symptomatic COPD. Pharmacoeconomics. 2015;33(5):467–88. DOI: 10.1007/s40273-015-0252-4
10. Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behavior across countries: disease-Specific Programmes – a means to understand. Curr Med Res Opin. 2008;24(11):3063–72. DOI: 10.1185/03007990802457040
11. Charlson ME, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. DOI: 10.1016/0021-9681(87)90171-8
12. Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–6. DOI: 10.1136/thx.54.7.581
13. Jones P, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54. DOI: 10.1183/09031936.00102509
14. EuroQoL Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. DOI: 10.1016/0168-8510(90)90421-9
15. Jenkins DC, Stanton B, Niemcryk SJ, et al. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41(4):313–21. DOI: 10.1016/0895-4356(88)90138-2
16. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. DOI: 10.1097/00005650-198601000-00007
17. European Society for Opinion and Marketing Research (ESOMAR), International Code of Marketing and Social Research Practice 2007. http://ethics.iit.edu/ecodes/node/5178. Accessed Jan 13, 2016.
18. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30. DOI: 10.1016/0167-6296(86)90020-2
19. Menn P, Heinrich J, Huber RM, et al. Direct medical costs of COPD—an excess cost approach based on two population-based studies. Respir Med. 2012;106(4):540–8. DOI: 10.1016/j.rmed.2011.10.013
20. Fédération Hospitalière de France. GACAH 2009. 2009 Available from: http://www.fhf.fr/Actualites/Finances-BDHF/comptabilite-analytique/GACAH-2009. Accessed Jan 13, 2016.
21. Ministero della Salute. Proposta metodologica per la valutazione dei costi dell’emergenza. 2007 Available from: http://www.mattoni.salute.gov.it/mattoni/documenti/11_Valutazione_costi_dell_emergenza.pdf. Accessed Jan 13, 2016.
22. Department of Health. NHS reference costs: financial year 2011 to 2012. 2012 Available from: https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012. Accessed Jan 13, 2016.
23. Échantillon Généraliste de Bénéficiaires. 2014. Available from: http://www.iresp.net/iresp/files/2013/04/091020182511_pos093_echantillon_g.pdf. Accessed Jan 13, 2016.
24. Freytag A, Storz P, Hagenmeyer EG, et al. Direct cost of treatment of COPD in a German sickness fund. iHEA 6th World Congress, July 8–11, 2007, Copenhagen; 2007.
25. SDO. Rapporto annuale sull’attività di ricovero ospedaliero dati 2010. 2010. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1690_allegato.pdf. Accessed Jan 13, 2016.
26. Garattini L, Castelnuovo E, Lanzeni D, Viscarra C, Gruppo di studio DYSCO VISITE. Durata e costo delle visite in medicina generale: il progetto. DYSCO. 4[2]. 2003.
27. PSSRU. Unit Costs of Health and Social Care 2012. 2012 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2012/. Accessed Jan 13, 2016.
28. Agenzia Nazionale per i Servizi Sanitari Regionali. Tariffe delle prestazioni specialistiche ambulatoriali aggiornato al 31 dicembre 2009. Available from: http://www.agenas.it/monitoraggio_costi_tariffe/2009_SPECIALISTICA_ex%20DM%2096per%20sito.pdf. Accessed Jan 13, 2016.
29. Murgia A, Scano G, Palange P, et al. Guidelines for long-term oxygen therapy. Update 2004. Rassegna Di Patologia Dell’Apparato Repiratorio. 2004;19:206–19.
30. Tarricone R, Lazzaro C. Valutazione degil aspetti economico-sanitari dell’ossigenoterapia domiciliare. 2003 Available from: http://www.gco.it/Valutazione%20degli%20aspetti%20economico%20sanitari%20OTD.pdf. Accessed Jan 13, 2016.
31. Lucioni DC, Donner CF, De Benedetto F, et al. I costi della broncopneumopatia cronica ostruttiva in Italia. Presentazione della prima fase dello studio ICE (Italian Costs for Exacerbations in COPD). Pharmacoeconomics. 2005;7(2):119–34.
32. Department of Health. Consultation on a strategy for services for chronic obstructive pulmonary disease (COPD) in England. 2010 Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213840/dh_113279.pdf. Accessed Jan 13, 2016.
33. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational Studies. Multivariate Behav Res. 2011;46(3):399–424.
34. Abadie A, Imbens G. Large sample properties of matching estimators for average treatment effects. Econometrica. 2006;74(1):235–67. DOI: 10.1111/j.1468-0262.2006.00655.x
35. Abadie A, Imbens G. Bias-corrected matching estimators for average treatment effects. J Bus Econ Stat. 2011;29:1. DOI: 10.1198/jbes.2009.07333
36. Abadie A, Imbens G. On the failure of the bootstrap for matching estimators. Econometrica. 2008;76(6):1537–58. DOI: 10.3982/ECTA6474
37. Abadie A, Imbens G. Matching on the Estimated Propensity Score. 2012 National Bureau of Economic Research Working Paper No. 15301 available at http://www.hks.harvard.edu/fs/aabadie/pscore.pdf. Accessed Jan 13, 2016.
38. Rosenbaum PR. Observational studies. Springer series in statistics; 2002. p. 1–17.
39. Craig R, Mindell J. Health survey for England 2013: Health, social care and lifestyles. Available at www.hscic.gov.uk/pubs/hse2013. Accessed Jan 13, 2016.
40. Punekar YS, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M. Implications of Chronic Obstructive Pulmonary Disease (COPD) on patients’ health status: a western view. Respir Med. 2007;101(3):661–9. DOI: 10.1016/j.rmed.2006.06.001
41. Voll-Aanerud M, Eagana TML, Wentzel-Larsenb T, Gulsvikc A, Bakkea PS. Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir Med. 2008;102:399–406. DOI: 10.1016/j.rmed.2007.10.012
42. Jones P, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in a primary care COPD population: implications for the new GOLD 2011 classification. Eur Respir J. 2013;42(3):647–54. DOI: 10.1183/09031936.00125612
43. Jones P, Brusselle G, Dal Negro R, Ferrer M, Kardos P, Levy M, et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim Care Respir J. 2012;21:329–36. DOI: 10.4104/pcrj.2012.00065
44. Britton M. The burden of COPD in the UK: Results from the confronting COPD survey. Respir Med. 2003;97(SUPPL. C):S71–9.
45. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med. 2003;97(SUPPL. C):S43–50.
46. Punekar YS, Shukla A, Muellerova H. COPD management costs according to the frequency of COPD exacerbations in the UK primary care. Int J Chron Obstruct Pulomn Dis. 2014;9(1):65–73. DOI: 10.2147/COPD.S54417
47. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–46. DOI: 10.1183/09031936.00195212
48. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81. DOI: 10.1164/rccm.201207-1299OC
49. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94. DOI: 10.1056/NEJMoa1407154
50. Punekar YS, Landis SH, Wurst K, Le H. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care. Respir Res. 2015;16:141. DOI: 10.1186/s12931-015-0295-2